DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs" report to their offering.
Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.
The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients.
As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.
Questions Answered:
- What is the pathophysiology of gastric cancer?
- How is gastric cancer diagnosed?
- What are the current treatment options?
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
- What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment?
- What are the most promising first-in-class targets for gastric cancer?
- Will the current first-in-class targets have a broader therapeutic potential across the industry?
- How do deal frequency and value compare between target families and molecule types?
-
How do licensing and co-development deals compare between
first-in-class and non-first-in-class profiles?
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3 The Case for Innovation
4 Clinical and Commercial Landscape
5 Assessment of Pipeline Product Innovation
6 Signaling Network, Disease Causation and Innovation Alignment
7 First-in-Class Target Evaluation
8 Deals and Strategic Consolidation
For more information visit http://www.researchandmarkets.com/research/jh35z6/frontier_pharma
